Biomarker-based Early Anti-inflammatory Therapy for severe COVID-19

Recruiting

• Conditions: coronavirus; COVID-19

• Registration Number: NL-OMON23631
• Lead Sponsor: Prof. Dr. L.G. Visser

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 250

Inclusion Criteria

Hospitalized patient with PCR confirmed COVID-19 infection
- Eighteen years or older

Exclusion Criteria

- Not able to give consent by representative of the subject

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biomarker profiles or signature which correlate with future clinical progression of patients infected with SARS-CoV-2 to multi-organ failure and acute severe lung injury requiring mechanical ventilation.